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Background: The status of the data-driven management of cancer care as well as the challenges, opportunities, and
recommendations aimed at accelerating the rate of progress in this field are topics of great interest. Two international workshops,
one conducted in June 2019 in Cordoba, Spain, and one in October 2019 in Athens, Greece, were organized by four Horizon
2020 (H2020) European Union (EU)–funded projects: BOUNCE, CATCH ITN, DESIREE, and MyPal. The issues covered
included patient engagement, knowledge and data-driven decision support systems, patient journey, rehabilitation, personalized
diagnosis, trust, assessment of guidelines, and interoperability of information and communication technology (ICT) platforms.
A series of recommendations was provided as the complex landscape of data-driven technical innovation in cancer care was
portrayed.
Objective: This study aims to provide information on the current state of the art of technology and data-driven innovations for
the management of cancer care through the work of four EU H2020–funded projects.
Methods: Two international workshops on ICT in the management of cancer care were held, and several topics were identified
through discussion among the participants. A focus group was formulated after the second workshop, in which the status of
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technological and data-driven cancer management as well as the challenges, opportunities, and recommendations in this area
were collected and analyzed.
Results: Technical and data-driven innovations provide promising tools for the management of cancer care. However, several
challenges must be successfully addressed, such as patient engagement, interoperability of ICT-based systems, knowledge
management, and trust. This paper analyzes these challenges, which can be opportunities for further research and practical
implementation and can provide practical recommendations for future work.
Conclusions: Technology and data-driven innovations are becoming an integral part of cancer care management. In this process,
specific challenges need to be addressed, such as increasing trust and engaging the whole stakeholder ecosystem, to fully benefit
from these innovations.
(J Med Internet Res 2020;22(12):e22034) doi: 10.2196/22034
KEYWORDS
neoplasms; inventions; data-driven science
Introduction
Background
The morbidity and mortality associated with cancer are rapidly
increasing globally because of population growth and aging,
reflecting the changes in the prevalence and distribution of major
risk factors of cancer [1]. These global trends have resulted in
more people living with or beyond cancer. As such, there is a
greater need to improve and optimize cancer care services
throughout diagnosis, treatment, rehabilitation, and end-of-life
care. Modern technologies, often enabled by the availability of
big data and advanced analytics, have demonstrated the potential
to enhance the current level of quality of cancer care, for
example by improving information access, informing and
sharing clinical decision making with patients, and facilitating
communication and support for coliving with the illness.
Pioneering research is now being conducted in the field of
cancer care technology, resulting in the development of novel
solutions to a diverse spectrum of problems in this area.
However, the process of evaluating these innovations and their
operation within a real-world context is at a less advanced stage.
The clinical assessment of technology poses many challenges
and is influenced by numerous variables. As a result, there is
an emphasis on the early evaluation of technology by including
key stakeholders throughout the design and development phases
(sometimes referred to as a cocreation process).
Objectives
Evidently, as researchers involved in the creation of novel
technologies for cancer care, we must consider and share both
the innovative concepts being developed as well as how they
are being assessed and accepted in real-world or clinical settings.
To this end, an international workshop was convened to consider
the current status of technological and data-driven innovations
in cancer care, to identify key challenges and opportunities, and
to formulate recommendations aimed at accelerating the rate of
progress in the data-driven management of cancer. The two
workshop instances led to a series of publications. This paper
discusses key topics arising from the workshops and subsequent
discussions among their participants.
Methods
An international expert consensus-building workshop named
Tech4Cancer [2] was held in two instances; the first was held
in June 2019 in Cordoba, Spain, along with the computer-based
medical systems [3] international conference, and the second
was held in October 2019 in Athens, Greece, along with the
Institute of Electrical and Electronics Engineers (IEEE)
Bioinformatics and Bioengineering [4] international conference.
The workshops attracted significant international participation;
more than 40 participants attended these events, where they
focused on discussing global trends for technological and
data-driven innovations in cancer care.
The workshop was supported by four European Union (EU)
projects, namely BOUNCE, CATCH ITN, DESIREE, and
MyPal, funded by Horizon 2020 (H2020). The BOUNCE project
[5,6] considers clinical, cancer-related biological, lifestyle, and
psychosocial parameters to predict individual resilience
trajectories throughout the cancer continuum. Eventually, the
target is to increase resilience in breast cancer survivors and
help them remain in the workforce and have a better quality of
life. DESIREE [7], on the other hand, aims to provide a
web-based software ecosystem for personalized, collaborative,
and multidisciplinary management of primary breast cancer by
specialized breast units, from diagnosis to therapy and
follow-up.
MyPal [8] aims to foster palliative care for people with cancer
by leveraging patient-reported outcome (PROM) systems
through their adaptation to the personal needs of the person with
cancer and his or her caregivers [9]. In this regard, MyPal
designed two novel eHealth interventions based on electronic
PROMs to offer advanced palliative care services to adult
patients with cancer and children with cancer. MyPal
interventions are delivered via a sophisticated eHealth platform
developed by the project. The interventions and the platform
itself will be assessed through two multicenter clinical studies
(one for the case of adults and one for the case of children),
which will take place throughout Europe. CATCH ITN [10] is
a PhD training network, with academic and industry partners
across Ireland, Spain, and Denmark. Research within CATCH
ITN focuses on the development and use of technology to
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improve the quality of life of individuals living with and beyond
cancer.
The primary deliverable from this workshop was a set of articles
that summarize key issues already published by IEEE. During
the paper presentation, several topics were identified through
discussion among the participants. After the second instance of
the workshop, participants were invited to participate in a focus
group discussing status, challenges, opportunities, and
recommendations in the area of technological and data-driven
cancer management; the outcome is reported in this study.
The writing group met by teleconference, and participants were
asked to propose topics according to their interest and expertise
and to select topics that they could actively contribute to. Several
topics depicting challenges, opportunities, and recommendations
were selected. Subsequently, leaders for each topic were
identified and a structure was proposed. A formal consensus
process was not used; however, the structured and open
discussions did not reveal any fundamental disagreements about
the nature of the topics, although the discussions supported the
refinement and specificity of topics. Once all contributions were
collected, a homogenization and integration process led to a
final draft, where all participants commented and discussed,
leading to the final submitted version.
Results
Patient Engagement and Participatory Design
A fundamental requirement for the effectiveness of any eHealth
intervention, including interventions addressed to patients with
cancer and survivors, is a certain level of engagement by the
patient [11], who is the main beneficiary of the intervention
[12]. The lack of engagement of patients with eHealth
interventions is linked to low motivation and adherence to the
intervention, leading to high dropout rates and eventually
affecting treatment outcomes and effectiveness [13]. The issue
of patient engagement has cast a shadow over the enthusiasm
for the potential of eHealth [14].
Formulating a concrete definition of patient engagement in the
context of eHealth is a challenge by itself [14], as there is a lack
of consensus on what the term engagement entails and because
different fields (eg, computer science, psychology, and
behavioral health) conceptualize it differently. A working
definition comes from the Canadian Institutes for Health
Research in the framework of the Strategy for Patient-Oriented
Research: patient engagement is the meaningful and active
collaboration of the patient in governance, priority setting,
research, and knowledge translation [15]. Some researchers
have defined engagement in terms of the level of activation of
the patient in the management of their own health [16]. Certain
definitions rely on psychological processes related to user
perceptions and experience, whereas others consider engagement
as a purely behavioral construct, synonymous with intervention
usage [17]. Consequently, engagement is often used
interchangeably with adherence, which refers to whether the
intervention is used as intended by its developers [18,19]. This
is the definition of patient engagement that is primarily
considered in the context of this study.
The situation is not significantly better when it comes to the
assessment of patient engagement. The lack of consensus in the
conceptualization of user engagement makes the design of
appropriate universal or even widely applicable assessment
instruments difficult. Instead, most research efforts propose
solutions for assessing user engagement for very specific
purposes, modalities, and contexts pertaining to eHealth
[11,20,21]. Focusing on mobile health (mHealth), a prominent
subfield of eHealth, a recent scoping review analyzed 41 studies
and developed a library of 7 analytic indicators to evaluate
effective engagement with consumer mHealth apps for chronic
conditions, namely the (1) number of measures recorded, (2)
frequency of interactions logged, (3) number of features
accessed, (4) number of log-ins or sessions logged, (5) number
of modules or lessons started or completed, (6) time spent
engaging with the app, and (7) number or content of pages
accessed [22]; this work is of particular relevance to care for
cancer, which currently tends to be considered a chronic disease
[23].
The scientific literature sheds some light on the techniques that
have been employed to achieve, maintain, and improve patient
engagement. According to a psychology study [24], patient
engagement techniques are categorized as follows:
1. Behavioral techniques, such as motivational interviewing,
goal setting, and planning, which are related to patient
actions when managing their health condition.
2. Cognitive techniques, such as question-asking tasks and
psychoeducation sessions, which are related to patient
thoughts and received information concerning their health
condition.
3. Emotional techniques, such as positive psychology exercises
and expressive writing tasks, which are related to
experienced patient feelings and emotions when adjusting
to their new health condition.
Most interventions developed for older adults employ patient
engagement techniques from behavioral and/or cognitive
categories, but not all categories [24]. The latter is also the
conclusion of a systematic review of eHealth for patient
engagement [25]. Moving beyond the psychology-oriented
categorization, other patient engagement techniques, such as
shared decision making and brief negotiated interviewing, have
also been employed; in fact, interventions have been designed
to integrate both techniques for engagement optimization [26].
Personalization has also been adopted in some studies as a
patient engagement technique [16,27].
However, the main barrier in building a critical mass of literature
on patient engagement with eHealth systems is the fact that very
few studies address or report the topic. For instance, a systematic
review on published trials discovered that only 23 of 2777
reviewed trials reported any patient engagement activities [28].
The literature review that was conducted in the framework of
a different study focusing on older patients concluded that
interventions to engage patients are generally scant and often
poorly described [24]. In addition, in a recent systematic and
mapping review on eHealth interventions employing electronic
patient-reported outcomes (ePROs) for palliative cancer care
conducted in the framework of the MyPal project [29], 17 of
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24 eligible ePRO-based palliative care interventions for patients
with cancer did not take patient engagement into account in the
development or evaluation of the proposed digital health
intervention. This may have been one of the reasons for the high
attrition rates reported by the studies. Furthermore, four other
studies recognized—mostly retrospectively—the need for patient
engagement, and some attempted to measure it. Only 3
remaining studies actively attempted to optimize patient
engagement during the design of the eHealth intervention or
system.
Opportunities
In contrast to the other challenges discussed in this work, the
solution to patient engagement may not be rooted in technology
itself but rather related to the way technology is designed. To
this end, there is a growing body of research demonstrating the
value of cocreation and participatory design in the development
of novel digital health services, including services for cancer
care. Participatory design is one of the pillars of the
revolutionary predictive, personalized, preventive, and
participatory (P4) cancer medicine [30,31], and it requires the
active involvement of users in the design or development phase
of an eHealth system. Participatory design can provide a unique
perspective on user acceptability, system usability, and the
feasibility of the overall effort [32]. By involving a
representative sample of a population of patients with cancer
in the design or development of an eHealth system or service,
one can eventually build an innovative solution that is expected
to have good engagement with the target population.
The main barrier is a lack of research culture for considering
the involvement of the end user (ie, in our case, the patient with
cancer) in the design process. Despite this barrier, participatory
design is expected to become the norm in eHealth technology
development in the upcoming years.
Recommendations
The MyPal project (see the Methods section) is an example of
a research effort that has committed to a participatory design
approach, implemented primarily via a series of focus group
discussions on eHealth interventions to be developed with the
participation of all the involved stakeholders (patients as well
as their informal carers and treating health care professionals)
[33].
The use of the participatory approach as early as possible in the
design of innovative technological solutions for patients with
cancer presents a good opportunity to improve patient
engagement [34]. The methodological tools, coming mostly
from the field of qualitative research (eg, semistructured focus
group discussions), are mature enough to support this design
paradigm in eHealth, as these have been extensively validated
in more generic software engineering environments. The
employed participatory design process has driven the
development of the MyPal platform for palliative cancer care
and has provided a series of generalizable guidelines or
recommendations for the successful application of participatory
design processes for patients with cancer engagement, which
are as follows:
1. Participatory design should start as early as possible in the
development lifecycle of an eHealth system or service, and
it should rely on established methodological tools.
2. Representative samples of the intended patient populations
need to be selected for participation in the co-design and
cocreation activities. This is especially important for
heterogeneous patient populations.
3. Participatory design findings should be fused with other
sources of knowledge (eg, a screening of unmet patient
needs from cancer care in the scientific literature).
These recommendations can complement pre-existing published
efforts to deliver more generic guidelines for developing
engaging eHealth technologies. For example, the work presented
in Karekla et al [14] specified 10 recommendations for
researchers and clinicians interested in developing an engaging
eHealth system. These recommendations are organized around
4 dimensions, namely a priori theoretical planning,
human-computer interaction, tailoring and targeting to user
groups, and active assessment of use. The eHealth technology
development framework presented in Gemert-Pijnen et al [35]
can also serve as a source of akin recommendations. Although
the main goal of the framework is to improve eHealth
technology uptake, some of the 6 working principles it
introduces are applicable to the pursuit of patient engagement,
especially the principle advocating for persuasive design
techniques.
Small Data Analytics
Data are fuel for any machine learning (ML) project [36]. It is
well known that deep supervised learning algorithms are
particularly data hungry—not only do they need a lot of data
samples but the data also have to be manually annotated
beforehand. However, big data sets with annotations (labeling,
structuring, etc) are very rare, as proper annotations must be
done by experts, and this is very expensive. Therefore, annotated
data sets are mostly small data. Annotating data in a less costly
manner remains to be a key challenge. A related challenge is
to reduce the dependence of ML on annotation.
ML, especially deep learning, can effectively learn with big
data. However, it cannot effectively learn with small data
because of various issues, for example, overfitting, noise,
outliers, and sampling bias, which can render the learned model
effectively useless. Effective learning with small data is a
challenge.
Opportunities
The annotation problem can be addressed via the use of
annotation tools or services in many ways, such as (1) providing
annotation tools so that annotation can be performed more
effectively and easily, existing tools include Lionbridge artificial
intelligence (AI) [37] and Computer Vision Annotation Tool
[38]; (2) outsourcing the annotation task to an annotation service
provider such as Amazon Mechanical Turk [39]; and (3)
enabling an expert to teach their ML model while building and
annotating their data set. However, none of these approaches
solve the annotation problem scientifically. There are ways to
deal with learning with small data problems, such as data
augmentation, transfer learning, regularization, and visualization.
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However, these methods require skilled people, and their
effectiveness is limited.
Another research question is regarding the procedure to add the
value of ML results under the constraint of the available
knowledge. Moreover, as knowledge and the latest clinical
evidence, such as clinical practice guidelines (CPGs), are usually
in paper-based formats and written in natural language, another
research question arises regarding the procedure to automatically
represent knowledge in a structured and computerized manner.
Recommendations
To solve the annotation problem scientifically, a desirable
approach is to design a new ML algorithm that requires minimal
feedback from human experts. This will only be possible if
domain-specific constraints can be imposed on the learning
process. This will reduce the model space as well as the variance
in learning. Thus, one research question is on the procedure to
reduce model space by domain-specific constraints.
An interesting approach to solve the learning with small data
problem is to use domain knowledge in the learning process or
knowledge-based learning. ML requires data as well as
knowledge (common sense and domain-specific knowledge)
implicitly or explicitly. When there are a lot of data, ML requires
a small amount of knowledge; when there is not much data, ML
requires a large amount of knowledge to reduce the model search
space. Model-based ML can be seen as an example of
knowledge-based learning, where knowledge can be specified
by experts in the form of variables and their dependencies. This
approach has been successfully demonstrated in various case
studies. One weakness, however, is that formalizing knowledge
is not a straightforward task, and it requires capturing experience
from clinicians through inverse engineering and making clinical
statements as explicit as possible for a computerized system. A
desirable approach is a knowledge-based learning algorithm
that (1) can be easily extended by data-driven findings and (2)
uses standardized terminologies to provide interoperability and
eases the updating and maintenance of the latest evidence. For
example, within the DESIREE project, a digital breast cancer
patient was formalized as a knowledge model ontology. The
ontology employed standardized terminologies to identify
univocally all identified clinical terms and procedures, which
included the knowledge reported in standardized guidelines
such as the National Comprehensive Cancer Network (NCCN)
[40] or the European Society for Medical Oncology [41]
guidelines in a computerized format, to be provided as
recommendations through a decision support system (DSS) for
multidisciplinary tumor boards during the decision-making
process. Although formalization of knowledge through a model
is almost a mandatory task in the very first steps of technical
developments, it is a very time-consuming and costly task.
Integration and Data Management
The multitude of successful instantiations of digital interventions
has opened exciting new directions for acquiring, delivering,
and sharing data, and has already proven the potential to
leverage cost-effective, patient-centered cancer care applications
[42-44]. Embedding patients into the iterative design process
of digital intervention has been shown to enable developers to
increase the relevance and effectiveness of the intervention [42].
Such treatments should be created with the acknowledgment
of patients’ knowledge, attitudes, beliefs, preferences, and
expectations of therapeutic outcome [45,46]. Thus, systems that
support clinicians would benefit from a redesign that aligns
cancer care more completely with patients’ needs and interests
[47,48]. ML, through its pervasive impact [49], has the potential
to provide a supportive tool for such a redesign task, given the
powerful data understanding, generalization capabilities, and
robustness [50].
Opportunities
Guided by the current state of the art, we identified a set of
opportunities for digital interventions related to patient-centered
cancer care. We have considered the most cited systematic
reviews in the last 3 years (ie, to extract the innovation
opportunities and technological limitations) and older systematic
reviews (ie, studies from 2011 to tackle the initial adoption and
strategies). These opportunities tackle the inherent challenges
that we identified in practice. The first challenge is data
collection and integration. Here, the core opportunity relates to
exploring and exploiting the aggregation of heterogeneous and
distributed data, including personal, professional, and
health-related information [51]. Such systems are typically
deployed as a platform to integrate retrospective, prospective,
and day-to-day care data. However, data interpretation and
translation remain to be an open challenge, whereas there is
also a constant need for standard data formats such as Digital
Imaging and Communications in Medicine and other standards
applicable to electronic patient record or electronic health record
(EHR) data. To address this, there is a clear opportunity to
interpret patient information for the patient themselves by
translating the clinical findings into an intuitive representation.
This would ensure that the delivery of health information is
done via a user-friendly interface.
When considering clinical data heterogeneity and the specificity
of patient data, data projection is another challenge that is
present in any technological intervention. We delineate a good
opportunity to build individualized clinical recommendations
based on the data interpretation projected in actions upon the
patient. This initiative will be based on the patient’s risk profile
and evidence-based guidelines (see the Extracting Patient
Portraits section).
Finally, with regard to data sparsity, such clinical setups face
the challenge of data completeness and augmentation. In contrast
to clinical trial experience, data completeness improves with
longitudinal care. This approach may be a solution to
minimizing missing data of PROMs in research or clinical care
settings in support of learning health care systems capable of
augmenting the data [52]. To maintain the validity of the
intervention, we believe that there is a good opportunity to
consider and consolidate clinical data with the comprehension
of lived experiences of patients, centered on patients [53].
Recommendations
On the basis of the identified challenges and opportunities, we
established a set of recommendations for the systematic
development of appropriate patient-centered digital interventions
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that ensure usefulness, adoption, and sustainability in cancer
care [54,55]. This process can be extended with learning and
generalization capabilities. ML algorithms excel at such tasks
and constitute invaluable tools for any digital intervention.
Next, we map the challenges that we identified before practical
recommendations. These recommendations can serve as a
reference design for technological interventions when looking
at integration and data management.
When addressing data collection and integration, we recommend
embedding continuous user feedback and iterative prototyping
in the intervention. This can be achieved by exploiting the
multimodal nature of patient data (ie, personal, behavioral,
professional, and health-related). ML techniques (ie, deep
learning and hybrid neural networks) can fuse heterogeneous
data in a common representation (ie, efficiently using very large
data sets containing health care use data, clinical data, and data
from personal devices and many other sources), as demonstrated
by the recent deep learning systems used on multi-omics data
sets to drive precision oncology care [56].
In terms of data interpretation and translation, we recommend
the use of tools to extract and represent the medical substrate
by synthesizing only relevant aspects in a declarative way. ML
techniques (ie, deep learning—recurrent networks with word
embeddings and distributed representations) can handle very
large and sparse data (eg, device data may only be available for
a small subset of individuals) to capture the sequential character
of the data and are suitable for modeling context dependencies
in inputs [57]. Such systems, which incorporate word
embeddings encoding syntactic and polarity information in the
language followed by deep neural network architectures, are
already used to extract and normalize parameters within
oncology care data.
To address the challenges in the area, we recommend the
development of clinical projections (ie, mappings) from
individualized patient recommendations to therapy plans that
embed temporal, procedural, and reasoning processes. ML
techniques, such as temporal hierarchical task networks, can
dynamically generate personalized therapy plans for oncology
patients [58], following a deliberative hierarchical planning
process driven by the procedural knowledge described in
oncology protocols [59]. Such instantiations use mappings to
attach reasoning and procedural knowledge representation as
well as their interpretation in a temporal planning process. The
planning process allows us to obtain temporally annotated
therapy plans that support decisions of oncologists. Moreover,
such an ML technique offers the ability to deal with complex
temporal and resource constraints, typical in cancer care.
Finally, tackling data augmentation, we recommend
incorporating the lived experiences of the patients [60]. ML
techniques, such as contextualized word embeddings, are
suitable for improved text augmentation independent of any
task-specific knowledge or rules and can process structured
questionnaires for patients who, for instance, developed
chemotherapy-induced peripheral neuropathy [61].
Extracting Patient Portraits
Individual biomedical and nonbiomedical patient characteristics
should guide any provided chronic care—digital or not. These
insights are used to develop and validate patient portraits that
can be employed in practice to determine optimal treatment
strategies for subgroups of patients with similar cancer care
needs and preferences. Building a patient portrait is hence an
endeavor that follows a bottom-up approach that includes patient
profiling based on patient phenotype algorithms [62-64];
intelligent patient profiling for the decision support of cancer
treatment by exploiting clinical and genomic data [65];
personalized predictive modeling and risk factor identification
using patient similarity [66]; and individualization beyond
biomedical factors to also include demographic, socioeconomic,
and psychological aspects [67]. To build a complete description
of the multiple dimensions describing each patient, we identified
a series of opportunities that describe all previously reviewed
work.
Opportunities
The series of opportunities we identified target the selection of
relevant heterogeneous and multimodal data correlated with the
diagnosis. To extract the opportunities and frame our
recommendations, we systematically analyzed a series of studies
ranging from genomic data and phenotypes to demographics
and psychological data. This methodology allowed us to capture
the most relevant dimensions for extracting a patient profile.
More precisely, the focus was on exploiting the correlations
among multiple data sources to build a digital patient portrait
consistent along all dimensions.
Such an initiative requires powerful data mining and ML
algorithms, which can provide an efficient and compressed
representation of a patient's digital profile, subsequently guiding
therapeutic schemes.
One challenge identified relates to data relevance. Here, there
is an opportunity to identify relevant genetic, phenotypical,
physiological, lifestyle, and medical data correlated with the
diagnosis. Exploiting such an opportunity can improve a patient's
profile and the overall effect of the intervention, especially in
progression-free survival [68]. Such studies demonstrate the
feasibility of intelligent patient profiling that can select, within
a clinically relevant time frame, a beneficial treatment for
patients with no other treatment options.
Given the data deluge describing each patient, exploring and
exploiting data correlations is another challenge we identified
in the context of extracting a patient’s profile. This challenge
provides a clear opportunity to exploit the correlations among
the multiple identified modalities toward building an individual
or personalized patient digital portrait that consistently captures
all dimensions of the patient’s disease evolution.
Such an exploration unveils another challenge, namely
multimodal data fusion [69], and the opportunity and potential
that fusing extracted knowledge have toward a personalized
therapeutic scheme [70]. Such systems, by combining data
describing complementary perspectives on the same biological
phenomena, can (1) separate correlated from discordant data,
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(2) extract the most informative features, and (3) estimate
disease progression.
The last challenge we identified as being crucial in any effort
to extract a patient’s profile is the possibility of embedding
individualized data (eg, age, gender, ethnicity, health conditions,
and social position) in patient cohorts [71]. Initial efforts were
made to include family history for risk assessment and early
detection of cancer; however, adherence to the study was low
because of the limited technological support. This challenge
brings along the opportunity to determine the population of
interest and use this information in the process of portrayal.
Recommendations
On the basis of the identified opportunities and related
challenges, we established a set of recommendations supporting
a digital intervention design that (1) exploits available data, (2)
extracts underlying correlations, and (3) integrates the multitude
of representations in a structured object guiding therapeutic
interventions in cancer care.
When addressing the challenge of identifying data relevance,
we recommend selecting the data or feature subset that best
characterizes the statistical property of a certain variable (ie, a
certain patient) subject to the constraint that these data or
features are as mutually dissimilar to each other as possible but
as marginally similar to a certain class of patients as possible.
For this task, ML tools such as minimum redundancy feature
selection (ie, Minimum Redundancy Maximum Relevance)
[72]) can be used to accurately identify the characteristics of
patient features or data and narrow down their relevance. Such
techniques provide an integrative approach to patient-centered
data and demonstrate the potential of feature selection in data
analysis and predictive patient-specific outcomes [73].
To address data correlations, we recommend the use of ML
models, such as long short-term memory (LSTM) [74] networks,
which can be used for their ability to effectively model varying
length time series data and capture long-term dependencies and
correlations. From modeling the patient life expectancy from
medical records [75] to complete patient trajectories [76],
modeling the disease trajectory and care processes, assumes
mining electronic medical records that are episodic and irregular
in time. Such models capture long-term temporal dependencies
and are well suited to modeling clinical data because the
evidence of certain conditions may be spread apart over several
hours or days, and important symptoms may present early on
in a patient’s trajectory.
The next challenge identified is the fusion of the available
multimodal data. Our recommendation is to use a data-driven
feature learning class of approaches. Typically, they are based
on deep networks that can directly learn the hidden
characteristics of the data from different sources. As such, we
recommend, for instance, the use of deep neural networks to
extract features from genomic and clinical data [77],
convolutional neural networks to extract features from pathology
images [78], and recurrent neural networks for text and medical
records data [79].
Finally, the last identified challenge is the possibility of
embedding individualization data in the patient profile. We
recommend performing individual cognitive interviews and
focus groups with patients to learn about their relevant needs,
experiences, fears, aspirations, and expectations.
From the ML point of view, a solution for developing
personalized patient embeddings that is capable of processing
such data is a combination of well-proven autoencoder methods
with extensions to some of the metrics to account for data
sparsity and multimodality [80]. Such studies also provide a
methodology describing how these networks can be designed,
built, and applied to tasks of integrative analyses of
heterogeneous cancer data.
A patient portrait that can capture complex relationships in
physiological signals, nonbiomedical data, and personal data
embedding is key to accurately predict the stages of
interventions for different patients and is necessary for
successful personalized therapy.
Learning Patient Disease Trajectory for Personalized
Diagnosis
Cancer is remarkably heterogeneous across individuals. This
heterogeneity makes treatment difficult for caregivers because
they cannot accurately predict how the disease will progress to
guide treatment decisions. Therefore, tools that help to predict
the individualized trajectory of cancer can help improve the
quality of health care [81,82]. Given the assessment of the
current state of the patient (ie, patient profile, physiology,
neuroimaging, blood biomarkers, and physiologic testing) along
with the therapeutic scheme, a digital intervention would use
ML or predictive systems to infer disease evolution or remission
to be able to guide subsequent therapy scheme planning [83].
Such a trajectory can also support the detection of behavior
change in patients [84].
Opportunities
A significant need relates to making disease predictions by
leveraging baseline information and additional time-dependent
clinical markers as they are collected. Such an approach is the
focal challenge of personalized medicine: integrative analysis
of heterogeneous data from an individual’s medical history to
improve cancer care. We identified several key challenges and
associated opportunities linked to this.
The first challenge relates to the fact that markers in clinical
data are irregularly and sparsely sampled. Here, we identified
a valuable opportunity for handling data and choosing specific
latent variable models to summarize and extract information
from the irregularly sampled and sparse data. This should
simultaneously ensure sidestepping the issue of jointly modeling
the data-generating processes [85]. Such systems should build
a temporal representation of care trajectories in the form of a
time-ordered state sequence. Moreover, in addition to the routine
identification of key dates and events in patients’ care
trajectories, such systems should identify initially fragmented
data across numerous sources.
Another challenge identified relates to the learning of a disease
trajectory and is linked to the inherent computational
complexity. Imposed by the clinical setup, we identified an
opportunity to predict the entire disease progression trajectory
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from the observed patient records without many training labels
on the ground-truth stages that a patient acquired, in mechanistic
models of disease progression. A joint approach is prone to
alleviate the inherent variability in prediction.
This challenge opens the stage for the next challenging point,
namely continuous adaptation and updates in the face of disease
progression heterogeneity. In handling such a challenge, there
is a clear opportunity for continuous-time adaptation and updates
to new observations and new data (markers). This provides
novel computational methods for predicting, for instance, disease
phenotype from molecular and genetic profiling [86].
Finally, another challenge we identified refers to the observed
versus latent data artifacts. Addressing such a challenge demands
tools for capturing latent factors in disease expression and not
only observed features as a crucial aspect for patient-tailored
cancer therapies. We further elaborate this in the following
Recommendations section.
Recommendations
In this section, we match the challenges to practical
recommendations in designing digital interventions when
predicting disease trajectories for patients with cancer.
To handle irregularly and sparsely sampled markers in clinical
data, we recommend, from the ML perspective, the use of
discriminative models that condition on marker histories instead
of jointly modeling them. Such an approach will not be sensitive
to miss-specified dependencies across marker types and inherent
irregularities and sparsity. For example, functional data analysis
[87] can be employed for sequences of measurements that are
assumed to be samples from an underlying continuous function.
However, coefficient estimates can have a high variance in time
series.
However, the task of predicting the disease trajectory comes
with its inherent computational complexity. To address this
challenge, we believe that an ideal candidate would be a machine
model that grows linearly in the number of marker types
included in the model. This makes such a task applicable to
cancer prognosis, where many different markers are recorded
over time. Generative models can account for disease trajectory
shapes using components at the population, subpopulation, and
individual levels, which simultaneously allows for heterogeneity
across and within individuals and enables statistical strength to
be shared across observations at different resolutions of the data
[88]. Moreover, such systems can learn accurate and
interpretable structured representations for disease trajectories
by adapting their attention weights that determine the
dependence of future disease states on past medical history.
Independent of the prediction model, the challenge is to
continuously adapt and update in the face of progression
heterogeneity. From the ML point of view, we recommend the
use of a model capable of being applied dynamically in
continuous time and updated as soon as any new data are
available (eg, hidden Markov models). Such approaches can
model the transition of disease stages or states, which implies
that the progression is continuous, and the transition probability
to the future state relies only on the current state and the time
span. Instantiation of such causality-based ML was used to infer
the underlying somatic staging of tumors from next-generation
sequencing data [89].
Moving away from the modeling decision, the last challenge
lies in the observed versus latent data artifacts. We believe that
a powerful tool is an ML model that accounts for latent factors
and covariates influencing disease expression, as standard
regression models rely on observed features alone to explain
variability [90]. For example, LSTM models over physiological
word inputs from health records significantly improve
performance as their representation encodes important
information about what is normal for each physiological value
or is more robust to sparseness in the physiological data.
Technological Interventions in Cancer Rehabilitation
Over the past decades, early diagnosis, new drugs, and more
personalized treatment have led to impressive increases in
survival rates of patients with cancer. However, the most
mitigating side effects of commonly used therapies are a severe
problem in oncology, leading to dose reduction, treatment delay,
or discontinuation [91,92].
Opportunities
With the increasing number of cancer survivors, more attention
is being paid to persistent sequelae of tumor treatment and
supportive measures [93-95] used as adjuncts to mainstream
cancer care to control symptoms and enhance well-being
[96-100]. The broad literature overview allowed us to identify
a series of challenges and the associated opportunities that digital
interventions could offer in supportive care.
The first challenge we identified is the identification of
therapeutic sequelae. This challenge offers the opportunity to
develop interventions capable of assessing what deficits
(sensory, motor, and/or cognitive) a specific patient has as a
consequence of cancer therapy.
The next challenge arises when the intervention needs to
quantify the magnitude of therapy sequelae. Here, we identify
a clear opportunity to measure the level of deficit or dysfunction
induced by the therapy. This is crucial in (1) designing the
follow-up therapy scheme, (2) choosing a rehabilitation strategy,
and (3) determining the therapy trajectory and dosage.
The last challenge we identified is the adaptive parametrization
of rehabilitation. This challenge brings a valuable opportunity
to take steps toward personalized treatment, namely, to
parameterize the rehabilitation scheme according to the specific
deficit type and level to drive rehabilitation.
Recommendations
To cope with patient sensory, motor, and cognitive deficit
variability, it is necessary to perform a precise assessment of
the 3 different dimensions. We believe that the 3 main
challenges we identified as high-potential opportunities for
digital interventions are also good candidates for ML algorithms.
This technology can learn underlying correlations in patient
data and generalize for robust prediction [101]. The mapping
from the challenge to the recommendation is provided in the
remainder of this section.
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When tackling the identification of therapy sequelae, we
recommend exploiting and mining large sets of structured and
unstructured data describing a patient to identify correlations
among various data types and how they map to a certain type
of dysfunction. We propose the use of semisupervised
techniques (eg, transductive support-vector machines [102])
that will only require a limited number of labels to generalize
well.
Moreover, to address the magnitude of the therapy sequelae,
we recommend the use of deep learning models, especially
convolutional neural networks. This is because such networks
are capable of learning relevant feature representation from
unstructured data, such as pathological images or medical
records. This, subsequently, allows deep learning methods to
achieve good results in tasks such as regression, detection, and
segmentation, which underlie the magnitude estimation.
Finally, addressing the challenge of adaptive parametrization
of rehabilitation, we recommend using methods that combine
learning capabilities for regressing arbitrary nonlinear functions
(ie, deep learning—encoding the type of deficit covariance with
the magnitude) and adaptation through guided searches in
parameter spaces (ie, reinforcement learning—finding the best
parameters of the rehabilitation scheme—dosage, type, and
length that best fit the regressed function).
Addressing Current Interoperability Challenges
Patient data needed for the provision of the best treatment are
often scattered across different systems rather than stored in a
single location. Technologies that facilitate care coordination
through interoperability are improving, but a seamless flow of
information from one care setting to another still requires more
progress. Without having a full picture, it is difficult to provide
the best care in an era where cancer is considered to be a chronic
disease, and there is an increased demand for consistent
follow-up in terms of monitoring and early management of
symptoms that indicate that cancer might have returned.
Interoperability is a primary consideration to achieve
communication among applications, medical devices, and health
care providers [103], although the growing demand for
secondary use of clinical and administrative data increases the
pressure to solve relevant challenges [104].
The currently popular use of EHRs has alleviated some of the
barriers in using data from medical records for research,
although fully interoperable electronic medical record systems
are not yet a reality. Several efforts to develop and apply
standards in the collection, extraction, and integration of data
by standardization bodies, governments, the research
community, and industry are in progress [105] with the aim to
establish and adopt clinically relevant, integrated standards
covering the entire oncology sector. Organizations such as
Health Level Seven International [106] and Personal Connected
Health Alliance Continua [107] help to deliver standards-based,
open specifications that can support the flow of data from the
point of capture into EHRs in the same format and coded
content. Cancer-specific apps that exploit platforms and
interoperability standards, such as SMART [108] and Fast
Healthcare Interoperability Resources [109], are emerging
[110-112].
Standards, such as those developed in the United States and
Canada, to guide EHR vendors and public health central cancer
registries in the implementation of standardized electronic
reporting [113-115] can be used with third-party terminologies.
It is a fact that some data resolution may be lost during the
process of mapping EHR fields to a formally described
abstraction layer, which may be alleviated by the use of
knowledge models such as ontologies as a knowledge
background mapper; however, these common interfaces support
queries across EHRs or the extraction of patient data in the same
format to allow the merging of patient sets between numerous
institutions.
Opportunities
Health information technology (IT) brings clinical data and
patient information together and guides oncologists in making
evidence-based care decisions that lead to improved outcomes.
The potential benefits of interoperable interconnected tools and
health systems are particularly important for oncology [116],
as providing cancer-wide care depends on access to accurate
and complete information as well as extensive coordination
among patients, caregivers, and diverse provider groups through
treatment and survivorship. Connecting the EHR has the
potential to support diagnosis assistance for complex patients
[117].
Data must be able to provide a complete look at the patient’s
medical history so that physicians can see what cancer medicines
and treatments did or did not work. Clinicians also need to be
able to avoid recommending the same procedure twice,
prescribing a medicine the patient already tried, or missing
results from a diagnostic test.
The need for consolidation and standardization efforts to create
interoperable solutions [105] and the need for the cancer
informatics community for national initiatives for data
standardization and large-scale multidisciplinary research
collaborations are timely and critical. In addition to supporting
cancer care, cancer-related standards will help improve
surveillance and research. Similar to migration from paper to
electronic records, the shift toward data interoperability between
EHR vendors may require policy changes [118,119].
Recommendations
As already proposed by [120], enabling interoperability among
institutions and individuals that support care delivery across the
cancer continuum is considered essential. Doing so requires
developing, testing, disseminating, and adopting technical
standards for information related to cancer care across the
continuum to optimize the flow of information to serve the
needs of caregivers, patients, and providers. To achieve this,
standard open application programming interface platforms
should be developed and used to facilitate the development of
cancer-related apps.
As mentioned in [121], standards and protocols that aim to
enhance the interoperability of different data sets are a highly
relevant field for policy action. Incentives for the promotion of
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standards for the interoperability of clinical data, such as EHR
or genome experiment data, should be developed, promoted,
and incentivized to allow for the pooling of data, and comparison
of system-level research should be provided for the comparison
of research outcomes.
The open use and sharing of big data, without compromising
patients’ rights to privacy and confidentiality, should be
promoted.
Patient-Clinician Shared Decision-Making Processes
Current clinical care is gradually moving toward
patient-clinician shared decision making, as patient involvement
can provide insights into best health states or outcomes in each
case, apart from establishing a partnership that will help
clinicians understand their patients’ preferences [122]. In a
complex disease, such as cancer, making a clinical decision is
a difficult task because of the trade-off between the level of
treatment benefits and the impact that adverse events or
symptoms could have on the patient’s life. This is especially
crucial in cases where the expected medical outcomes are similar
for different clinical procedures (ie, also referred to as
equipoise), requiring an individualized and personalized health
care process involving the clinician and the patient in a close
interaction for the best decision making [123]. Nevertheless,
actual CPGs still do not include or barely mention the impact
of patient preferences along with clinical evidence.
Opportunities
It is necessary to overcome many barriers to ensure success in
the inclusion of patient preferences during the decision-making
process and to track their impact in the care services provided
[124]. First, patient preferences should be considered as
population knowledge that follows some general trends and not
just as individual one-off cases or subjective and variable
factors. This would allow including them along with the clinical
evidence reported in the studies to identify preference-sensitive
decisions (eg, decisions having lifelong implications or an
uncertain benefit to the patient, unclear or conflicting evidence,
risk of having side effects that negatively affect the patient’s
quality of life) of high levels of uncertainty about the best
clinical procedure to follow [125].
Recommendations
As a complex disease, cancer involves many clinical specialties,
with the need of creating a clear taxonomy (ie, systematic
categorization) for patients’ preferences that will serve as a
standardization over all involved disciplines (eg, analysts,
clinical psychologists). This kind of approach would help in the
harmonization of the different points of view on the
measurement of patients’preferences by labeling and extracting
this information in a processable and understandable way
[126,127]. Finally, with regard to the previous points, building
a methodology to synthesize the current knowledge on
preference trends to be able to describe preference-based
decisions along with clinical-based evidence would have a great
impact on health care performance, as it has been proven that
preferences strongly influence the decision-making process
[128,129].
Assessment of Clinical Evidence-Based
Recommendations, Including PROMs
As presented in the previous sections, the evidence used in
medical practice is based on clinical guidelines, which are often
used as the evidence basis for the clinical DSS (CDSS) [130].
These guidelines are developed by multidisciplinary groups and
are based on a systematic review of the scientific evidence,
and their recommendations are explicitly linked to the
supporting evidence and graded according to the strength of
that evidence [131]. As reported by Harbor et al [131], the levels
of evidence of the recommendations are based on study design
and the methodological quality of individual studies, which is
called the quality of evidence. Therefore, the latest approach
also considers the strength of the recommendations, which is a
trade-off between benefits and harms of a treatment, considering
the quality of evidence [131,132]. Several oncology guidelines,
such as the NCCN CPGs in Oncology [133] applied in
DESIREE, provide quality of evidence measure, and it is up to
the clinician to consider the strength of the recommendation
depending on the specific patient situation. However, the
subjective measures of patients with cancer, such as fatigue
affected by oncological treatments, have not been systematically
considered during the decision-making process. Making this
information available during the decision-making process also
provides other relevant and real-world quality measures to the
treatment recommendation to best support clinicians and patients
in their treatment decisions.
Opportunities
CDSSs provide the opportunity not only to quickly access the
latest available evidence but also to incorporate new sources of
information that can support the decision-making process. At
the same time, the new IT era enables the acquisition of PROMs
using questionnaires or even more sophisticated wearables that
can measure activity, sleep, or other vital signs that can be
translated to patient outcomes. These automatic ubiquitous
technologies increase the knowledge required by patients.
Processing these data and deducing the desired results will be
very helpful. For example, tracking the daily activities of a user
provides estimates of how active a patient is, which can be
correlated with their depression and/or fatigue levels (variables
that are gathered using questionnaires such as the European
Platform for Cancer Research—Quality of Life Questionnaire
with 30 items). Other techniques could also aid the acquisition
of patient outcome information, such as the Ecological
Momentary Assessment tests (short questionnaires that are sent
to the patient frequently to obtain updates on their status). Thus,
the collected data could be used to assess how good the
treatment given was for each patient, not in the scope of a
randomized control trial but in the real-world environment,
without having a specific patient population, but the whole
population.
Recommendations
In this context, in the DESIREE project focusing on primary
breast cancer, new ways of including PROMs to assess guideline
recommendations were explored. The aim of including PROMs
does not conflict with the quality of evidence and strength of
recommendation measurements but provides other quality
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attributes that contribute to the decision-making process,
considering the patient status reported by the patients
themselves.
There are some specifications that should be considered for this
quality assessment, which could be named questionnaire
based–patient-reported outcome measures, and they include (1)
consideration of standard questionnaires for each medical case,
such as the International Consortium for Health Outcomes
Measurement questionnaires [134], (2) definition of specific
protocols to assess the results of the questionnaires, and (3)
determination of how these results should be used during the
decision-making process.
Ambiguity on Clinical Guidelines Used for Clinical
Decision Support
When implementing CPGs, several characteristics must be
considered to ensure both good health care quality levels and
clinicians’ satisfaction. They must assure the validity and
reliability of their clinical content, along with their clinical
applicability in real clinical settings, and must be clear when
defining the procedures to be followed in the current clinical
performance procedures within a health care system [135,136].
Nevertheless, several barriers cause the dissemination of the
guidelines to be tedious and difficult, mainly because of the
ambiguity of the knowledge defined in them. The lack of
awareness and familiarity with the recommendations provided
in the guideline, a lack of agreement due to different clinical
interpretations and simplification of the clinical knowledge
reported in the guidelines, and the lack of outcome expectancy
are some of the reported barriers that cause a lower adherence
of clinicians to guidelines and have an effect on their
implementation, compliance, and adherence in real clinical
settings [137,138].
Opportunities
Actual trends move toward highly interactive computerized
systems focusing on intuitively presenting complex clinical
cases, where clinicians may access and check computerized
clinical data and take away insights from all of this information
in a more natural and intuitive way, alleviating the ambiguities
of the guidelines through a data-driven approach guided by
previous practice [139]. The digital implementation of the CPGs
provides evidence-based decision support (ie,
computer-interpretable guidelines [CIGs]) [140]. To achieve
this, the knowledge available has to be formalized in a manner
that is correct and of good quality, by following a consistent
and adequate methodological workflow of the clinical processes
and objectives, trying to reduce or provide some solutions to
the paper-based guidelines ambiguities [141].
Recommendations
The proposed directions for realizing these needs include the
promotion of standardized clinical terminology that facilitates
the understanding and univocal interpretation of the clinical
data to be analyzed and the clinical knowledge formalized in
the CIGs (eg, the Breast Imaging Reporting and Database
System standard for breast anomalies [142]); to be effective,
clinical guidelines need to be integrated with the care flow and
should provide patient-specific advice when and where needed.
Hence, their formalization as CIGs should make it possible to
develop CIG-based DSSs, which have a better chance of
affecting clinician behavior than narrative guidelines. This will
help in providing optimal personalized guideline-based
recommendations, avoiding ambiguities, and at a reasonable
cost and implementation effort [143].
Up-to-Date Clinical Evidence Guidelines for CDSS
Clinical guidelines are tedious to develop, and it is even more
difficult to interpret and put them into a computer-interpretable
way. This usually requires the close collaboration of knowledge
engineers and medical experts. A closely related and important
issue is the guideline development process or how CPG
development working groups are composed. Usually, these
teams comprise quality auditors or managers who are guided
by their opinions, interests, and experience and intend to
formalize evidence, seeking appropriateness of the provided
recommendations but ignore the iterative and causal reasoning
of clinicians [144]. Depending on the clinical context and
according to the approaches followed for developing,
disseminating, and implementing them in practice, CPGs can
be more or less successful when reporting the latest clinical
evidence [145]. Thus, the rapid advances in clinical practice
have made the task of updating the guidelines used for the CDSS
more challenging. In particular, in oncology, the number of
discoveries is increasing rapidly. As reported by Beatty [146],
drug label information and indications do not always keep up
with meaningful advances in oncology resources. However,
clinicians may be aware of the potential benefits of a particular
therapy. Hence, Beatty [146] reports that continuous vigilance
(in the form of continuing medical education and literature
review) is a survival attribute for medical oncologists.
Consequently, there is also a challenge to update the CIGs and
have up-to-date guideline-based CDSS.
Opportunities
In this context, it is crucial to have tools supporting the easy
updating of CIGs used for CDSS by clinicians themselves or
knowledge engineers who do not necessarily have to understand
the technology and/or the programming language used. Thus,
interfaces that are easy to use and easy to understand are
required for this purpose. This limitation was highlighted in the
DESIREE project; however, this is an issue not only for cancer
care but also for other clinical specialties.
Recommendations
Therefore, we propose an authoring tool for CPG formalization
[147] that should at least fulfill the following requirements: (1)
enable the input of guidelines’ information in an easy and visual
manner, such as the form of rules or flowcharts, and (2) enable
the modification of CIGs previously formalized in the system.
In addition, future work should focus on providing a tool for
detecting modifications in guidelines as well as semiautomate
the formalization of guidelines, using natural language
processing.
Trust and Reliance on Cancer Care
The change in both hardware and software over the past decade
has been remarkable. Equally noteworthy has been the
ever-increasing internet speed and the accompanying growth
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in the demand for connectivity. This growth and development
have increased our ability to take on challenging projects to
improve early diagnosis and improve the quality of cancer care.
However, most discussions relating to health data and associated
analytical tools often emphasize data privacy and security at
the expense of other topics. These talks often overlook the
dynamic nature of both health data and the software used in the
analysis of those data. In addition, the popularity of
internet-based apps and the use of such tools by patients for
self-diagnosis necessitate a call to action. There is a need to
examine the reliability and trustworthiness of health-related
computational tools used in diagnosis and DSS by health care
providers. Here, we will focus on the reliance and reliability of
computational tools with an emphasis on cancer care and
diagnosis.
Opportunities
Reliance and reliability of information in health care are
incredibly important. These attributes are particular when it
comes to genetic information associated with cancer, which is
highly critical in the development of optimal clinical
intervention strategies. With an increasing number of people
falling victims to medical misinformation and propaganda on
the internet [148], advocacy to develop reporting and assessment
standards has been long overdue. The internet undoubtedly
provides patients with countless sources of health information
related to cancer diagnosis and care, some of which represent
the gold standard, whereas other sources remain to be of ill
repute. The internet promotes decentralization and web
democratization of access. Having an open-source or access
model certainly helps to promote this agenda. These models
provide help and are available to many without the control of
smaller powerful broker or agents. However, it challenges the
core process of software development, which includes
specification, design, development, verification, validation, and
management. Although inspection or peer review is the method
of choice to check for static processes and software testing a
true validation and verification method to check the system, the
former fails to check emergent properties such as reliability and
performance.
There is no turning back from this path of dependence on the
tools and information available via the internet. People have a
reasonable expectation of establishing trust and validation of
these tools. Initiatives such as the Secure Socket Layer
certification system, implemented for encrypting sensitive
information sent across the internet or the use of digital badge
to indicate or attest to adhere to an acceptable standard and/or
individual skill competency (seal of approval from prominent
institutions) or the use of the message-digest algorithm 5 (MD5)
hash to ensure data integrity work to build and maintain that
trust. Health IT requires a method to assure the credibility of
the results generated by various computational tools available
on the web. Unfortunately, none of the previously listed
solutions are applicable to health software because of the
dynamic nature of data as well as the software (as many deviate
from the original specifications for which acceptable test and
peer review of the result exist).
Recommendations
Having reliable information alone is not sufficient for people
to construct their foundation of trust. People may have a distrust
on the reliability of official information on certain topics because
of previous unpleasant experiences. One conclusion that can be
drawn from our experience in developing relevant computational
tools over the past decade is the questionable credibility of the
results obtained from such tools. A review of the literature shows
a great deal of volatility in the availability of health IT resources
and shows that providing explanations for software errors is an
acceptable approach. Building on this notion, a certificate that
discloses who is responsible and what tests are done or can be
done to validate or test the trustworthiness of the output,
something along the line of the MD5 checksum, could be
envisioned as an acceptable solution to address this issue. Such
a certificate could include the versions of the data and the
software in a report to help explain the deviation from the
previous version. This could be seen as a reasonable step in the
right direction before the availability of peer-approved
permanent solutions.
Trust in Computer-Aided Diagnosis Systems
An important issue emerging for decision support in medical
diagnosis is the trust that clinicians might have in the outputs
generated by a computer-aided diagnostic system. This is a
highly relevant issue for tissue characterization in general and
image-based tumor classification in particular. Hence, it should
be considered whether the metrics such as accuracy (ACC) and
area under the curve (AUC) correlate well with confidence in
the algorithms used in computer-aided design (CAD) systems.
If the CAD system provides a recommendation with moderate
or low confidence, then a radiologist may deem the
recommendation to be useless, even if the classifier being used
has a high overall value for ACC and/or AUC. However, if the
confidence is much higher, the clinician may deem the
recommendation more useful in supporting their decision
making. Therefore, building CAD systems in which clinicians
have confidence is essential if those CAD systems are to be
adopted and are to play a role in fully exploiting the range of
digital information available for assisting diagnosis.
Recent studies discuss the failure of CAD systems in terms of
a lack of trust by clinicians in the outputs that the CAD systems
generate [149-151]. When designing and evaluating an algorithm
within a CAD system, technical developers tend to report
metrics such as ACC and AUC to demonstrate the performance
of a classification method. However, such metrics do not
measure the degree of confidence in individual recommendations
made by the CAD system. For example, a CAD system may
produce a high AUC value very close to the optimal value of
1, but most of the cases might be classified with low confidence
(as measured by the likelihood or probability value associated
with the recommended class). Indeed, studies have shown that
the use of CAD systems that incorporate inadequate metrics
can be detrimental to diagnosis [152].
Opportunities
Exploratory studies for breast mass classification [153] and
classification of microcalcifications in mammograms [154]
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using data sets taken from the Curated Breast Imaging Subset
of DDSM [155] showed that although most classifiers produce
similar overall ACC and AUC values, their performances differ
significantly in terms of confidence measure. High ACC or
AUC does not provide a full indication of the confidence level
of a CAD system. This aspect of the usability of CAD methods
is a key but overlooked challenge. Most cancer CAD systems
have used ACC and AUC as the main evaluation metrics;
however, the probability outputs of the classifier must also be
considered and harnessed to measure the degree of certainty of
the system in its decision making. Hence, if clinicians are to
have confidence in the support provided by a CAD system, the
classifier that is chosen to be implemented as part of the system
should not necessarily be the one that performs best overall
using the standard metrics. CAD support systems must embody
reliable confidence measures as one of their key elements [156].
It is therefore essential that the domain of trust in CAD systems
should be explored to incorporate trust into the initial classifier
design when such algorithms are to be embedded into a cancer
CAD system.
Recommendations
To fully exploit the range of digital information available for
assisting diagnosis, it is important to identify and implement
specific actions to increase the trust of physicians in cancer
CAD systems and overcome the barriers to adoption of such
systems. Most cancer CAD systems have used ACC and AUC
as the main performance evaluation metrics; however,
confidence measures must also be considered, as the traditionally
used metrics are inadequate for informing clinicians in terms
of the confidence that they might place on the recommendations
provided. Besides, research in the design of classifiers that are
incorporated into CAD systems is essential if future CAD
systems are to be trusted by clinicians and adopted as a valued
and reliable, and indeed routine, element of the cancer diagnosis
process.
Regulatory Roadmap for Validating the Effectiveness
of AI–Based Models for Clinical Decision Making
Data and image analysis algorithms usually require regulatory
approval by the Food and Drug Administration (FDA) in the
United States and conformity assessment leading to a
Conformité Européenne mark in the EU [157], under the new
Medical Device Regulation. Both EU and US regulations
classify medical devices according to risk classes, and those
that fall under certain risk classes are required to undergo
clinical trials to be marketed [158]. To date, these guidelines
target systems with so called locked algorithms, that is,
algorithms whose functions do not change, rather than adaptive
ones, that is, whose behavior can change over time based on
new data [159]. Adaptive AI–based tools have the potential to
autonomously “adapt and optimize device performance in
real-time to continuously improve healthcare for patients.” The
FDA has already approved several AI- or ML-based software
as a medical device (SaMD), but these have only included
algorithms that are locked before marketing [160].
Opportunities
Regulations that aim to validate AI in a safe and transparent
way must consider doing so without compromising the potential
of AI. Moreover, characteristics of AI that may be seen as risks
such as biases in data, its blackbox nature, and model
degradation, among others, have to be included in the validation
process to better ensure safety and build public trust [161]. The
FDA recently proposed an approach that aimed to “have tailored,
pragmatic, and least burdensome regulatory oversight” while
validating the continued safety, effectiveness, and performance
of SaMDs. The framework recommends (1) establishing clear
expectations of quality systems and good ML practices, for
example, demonstrating analytical and clinical validation, (2)
creating SaMD prespecification sheets and algorithm change
protocols to qualify for a premarket review on the safety and
effectiveness of the AI-based tool, (3) preparing an approach
for AI- or ML-based software modifications (eg, data for
retraining), and (4) implementing mechanisms that support
transparency and real-world performance monitoring.
In the EU, there are no regulatory guidelines that specifically
cover AI in health care. Nevertheless, draft ethics guidelines
have been published by the High-Level Expert Group on AI in
April 2019, proposing 7 key requirements that AI systems
should meet to be realized as trustworthy AI: human agency
and oversight, including fundamental rights; technical robustness
and safety; privacy and data governance; transparency, diversity,
nondiscrimination, and fairness [162,163]; societal and
environmental well-being; and accountability. The guidelines
also propose technical and nontechnical methods to implement
the 7 key requirements and recommend that these should be
continuously evaluated and addressed throughout the AI
system’s life cycle.
Recommendations
The frameworks enumerated above are, however, still being
piloted or discussed. To properly define a regulatory framework
for users, stakeholders and use cases (data flows) should be
identified and defined. New regulatory frameworks should be
built to provide guidance for the validation or qualification of
AI tools within different scenarios and pathways (for nonclinical
or preclinical use or clinical use), taking into consideration the
adaptive nature of AI-based tools. The framework should
consolidate input from scientific experts and health authorities
and should take into consideration published relevant guidelines,
for example, from the High-Level Expert Group on AI, the
Medical Device Coordination Group and relevant implementing
EU legislation, and international regulations (eg, from the FDA).
Table 1 summarizes the various topics discussed, the related
works for each topic, the opportunities, and the
recommendations from the workshops.
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Table 1. Topics, opportunities, and recommendation in cancer care.
RecommendationsOpportunitiesTopic or section (references)
Patient engagement and
participatory design [11-29]
• Participatory design approach early and throughout
the design process
• Involvement of real users
• Identification of user needs
• Focus groups with stakeholder representatives• Unique perspective on user acceptability, usability,
and feasibility • Fuse findings with those from other sources
Small data analytics [36] • Design new machine learning algorithms that needs
minimal feedback from human experts
• Address the annotation problem via appropriate tools
• Enable experts to teach MLa models that automatically
• Use knowledge-based learning that can be extended
by data-driven findings easily and that uses standard-
build and annotate their data sets
• Automatically represent knowledge in a structured
and computerized way ized terminologies to provide interoperability and ease
the updating and maintenance of the latest evidence
Integration and data manage-
ment [42-50]
• Embed continuous user feedback and iterative proto-
typing in the intervention
• Exploiting aggregated, heterogeneous, and distributed
data
• Translating the clinical findings into an intuitive rep-
resentation for the patient
• Usage of tools to extract and represent the medical
substrate by synthesizing only relevant aspects in a
declarative way• Building individualized clinical recommendations
based on the data interpretation projected in actions • Development of clinical projections from individual-
ized patient recommendations to therapy plans thatupon the patient
embed temporal, procedural, and reasoning processes• Data completeness and augmentation
• Incorporation of lived experiences of the patients
Extracting patient’s portrait
[62-67]
• Exploit available data• Exploit correlations among multiple data sources to
extract patient profile • Extract underlying correlations
• Use data mining and machine learning to guide thera-
peutic schemes
• Integrate the multitude of representations in a struc-
tured object guiding therapeutic interventions in cancer
• Identify relevant genetic, phenotypical, physiological,
lifestyle, and medical data correlations with diagnosis
care
• Provide an integrative approach to patient-centered
data and demonstrate the potential of feature selection
in data analysis and predictive patient-specific out-
comes
Learning patient disease tra-
jectory for personalized diag-
nosis [81-84]
• Use of discriminative models that exploit conditions
on marker histories instead of jointly modeling them
• Handling data and choosing specific latent variable
models to summarize and extract information from
the irregularly sampled and sparse data • Focus on machine models which grow linearly in the
number of marker types included in those models• Learning of a disease trajectory is linked to the inher-
ent computational complexity • Use of a model capable of being applied dynamically
in continuous time and updated• Continuous adaptation and update in face of disease
progression heterogeneity • Exploit models that account for latent factors and co-




• Perform a precise assessment of patient’s sensory or
motor or cognitive deficit variability
• Cope with patient sensory, motor, and cognitive deficit
variability
• •Identify therapy sequelae Use machine learning algorithms to identify underly-
ing correlations in patient data and generalize for ro-
bust prediction
• Exploit and mine large sets of structured and unstruc-





• Develop, test, disseminate, and adopt technical stan-
dards for information related to cancer care across the
continuum
• Provide cancer-wide care
• Support diagnosis assistance for complex patients
• Provide a complete look at the patient’s medical his-
tory so physicians can see ineffective treatments • Optimize the flow of information to serve the needs
of caregivers, patients, and providers• Improve surveillance and research
• Develop and use standard, open application program-
ming interfaces
• Promote incentives for the pooling of data and com-
parison of system-level research
• Support open use and sharing of big data, without
compromising patients’ rights to privacy and confiden-
tiality
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RecommendationsOpportunitiesTopic or section (references)
• Create a clear taxonomy (ie, systematic categorization)
for patients’ preferences to serve as a standardization
• Harmonize different points of view to facilitate label-
ing and extraction of information in a processable and
understandable way
• Build a methodology to synthesize knowledge
• Inclusion of patient preferences during the decision
making and tracking of their impact in the provided
care services




• Explore new ways of including PROMs to assess
guideline recommendations
• Exploit PROMs in the decision-making process, con-
sidering patient status reported by the patients them-
selves
• Consider and use existing quality assessment specifi-
cations for PROMs
• Quick access to latest available evidence
• Incorporate new sources of information that can sup-
port the decision-making process
• Increase the knowledge required by patients
• Effectively assess how good the treatment given was
for each patient, not in the scope of a randomized
control trial, but in the real-world environment




• Promotion of standardized clinical terminology
• Integration of clinical guidelines with care flow
• Insight from complex clinical cases in a natural and
intuitive way
• Patient-specific advice when and where needed
Ambiguity on clinical
guidelines used for clinical
decision support [135-138]
• Generate tools that enable the input of guideline infor-
mation in an easy and visual manner and enable the
modification of CIGs previously formalized in the
system
• Provide a tool for detecting modifications on guide-
lines
• Semiautomate the formalization of guidelines using
natural language processing
• Create tools that support the easy updating of CIGsd
for clinicians
• Interfaces that are easy to use and understand are re-




• Provision of a certificate that discloses who is respon-
sible and what tests are done or can be done to validate
or test the trustworthiness of the output
• Include the versions of the data and the software in a
report to help explain the deviation from the previous
version
• Assurance of the credibility of results generated by
various computational tools available on the web
Trust and reliance on cancer
care [148]
• CAD support systems must embody reliable confi-
dence measures as one of their key elements
• Incorporate trust into the initial classifier design when
such algorithms are to be embedded into a cancer
CAD system
• Increase confidence in the support provided by a
CADe system
Trust in computer-aided di-
agnosis systems [149-152]
• Identify and define users, stakeholders, and use cases
(data flows)
• Build regulatory frameworks aiming to provide guid-
ance toward the validation or qualification of AI tools
within different scenarios and pathways
• Consolidate input from scientific experts, health au-
thorities, and published guidelines
• Validation of AI in a safe and transparent way without
compromising the potential of AI
Regulatory roadmap for
validating the effectiveness










This paper presents the key topics that were discussed as part
of two international workshops on the current status of
technological and data-driven innovations in cancer care. Key
challenges and opportunities have been identified, and several
recommendations have been made to facilitate the acceleration
of progress in the data-driven management of cancer. The
workshops presented the work that was being conducted in four
Horizon 2020 EU–funded projects, namely BOUNCE, CATCH
ITN, DESIREE, and MyPal. These projects provide a rich
landscape of the challenges and opportunities of the current
state of the art of new technologies in cancer care. The authors
have presented these issues and discussed recommendations
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that can be used for further research as well as practical implementation of such tools in cancer.
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